Molecular signature of Epstein-Barr virus infection in MS brain lesions
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 21, 2017
- Accepted in final form April 25, 2018
- First Published June 7, 2018.
Author Disclosures
- Monica A. Moreno, PhD,
- Noga Or-Geva, PhD,
- Blake T. Aftab, PhD,
- Rajiv Khanna, PhD,
- Ed Croze, PhD,
- Lawrence Steinman, MD and
- May H. Han, MD
- Monica A. Moreno, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Atara Biotherapeutics, Inc. 4360 Park Terrace Drive, Suite 100 Westlake Village, CA 91361 office: (805) 330-6526 mobile: (805) 637-4006
NONE
NONE
NONE
Atara Biotherapeutics, Inc. 4360 Park Terrace Drive, Suite 100 Westlake Village, CA 91361 office: (805) 330-6526 mobile: (805) 637-4006
NONE
NONE
First author, Monica Moreno, was funded by NIH T32 (AI07290-30) during the time of the study. This publication was not related to the project funded by Dr. Moreno's NIH T32.
NONE
NONE
NONE
NONE
NONE
NONE
- Noga Or-Geva, PhD,
NONE
NONE
NONE
NONE
Use of anti-third party cells for treatment of a variety of diseases including cancer and autoimmune disease or as protectors of genetically-engineered cell therapy. Patent EP2613801A2 Patent WO2017009853A1 Patent WO2017009852A1 Patent EP2613801B1 Patent CA2810632A1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Blake T. Aftab, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Atara Biotherapeutics, Inc., Senior Director Preclinical and Translation Science, 3 years
NONE
NONE
NONE
NONE
(1) Atara Biotherapeutics, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Atara Biotherapeutics, Inc. Stock/Stock Options, Medical Equipment & Materials: (1) Atara Biotherapeutics, Inc.
NONE
NONE
- Rajiv Khanna, PhD,
I am appointed on the scientific advisory board of Atara Biotherapeutics
I am appointed as a consultant for Atara Biotherapeutics
NONE
I am appointed as Editor-in-chief of Clinical & Translational Immunology Journal
I am listed as inventor on multiple international patents or patent applications which includes T cell epitopes and also immunotherapy for virus-associated diseases including manlignancies and autoimmune diseases
NONE
NONE
I am appointed as a consultant for Atara Biotherapeutics
NONE
NONE
NONE
I receive research and development funding from Atara Biotherapeutics.
I am currently recipient of multiple research grants from National Health and Medical Research Council (Australia).
NONE
NONE
I have stock options from Atara Biotherapeutics.
I have received licensing payments as an inventor from Atara Biotherapeutics
NONE
NONE
NONE
NONE
- Ed Croze, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am a consultant for Atara. Iris-Bay is my consultancy company
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence Steinman, MD and
Novartis, Receptos, Atreca, Tolerion, Teva, AbbVie
NONE
Celgene, AbbVie
MS Journal, Proceedings National Academy of Sciences
I have a patent pending on cytokines and type 1 interferons. I have multiple patents on antigen specific tolerance.
NONE
NONE
NONE
NONE
NONE
NONE
Atara, Celgene, Biogen
NONE
NONE
NONE
Stock options and board membership in Tolerion Board of Directors BioAtla
NONE
NONE
NONE
NONE
NONE
- May H. Han, MD
Novartis Inc, advisory committee (1)
NONE
University of California, San Diego (1) CMSC (1)
NONE
NONE
NONE
NONE
Sanofi-Genzyme (1)
NONE
NONE
NONE
NONE
NONE
NONE
Guthy Jackson Chartiable Foundation for NMO Research (1) Fondation Leducq (2)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Neurological Sciences (M.A.M., N.O., L.S., M.H.H.), Stanford University School of Medicine, Multiple Sclerosis Center; Interdepartmental Program in Immunology (M.A.M., N.O., L.S., M.H.H.), Stanford; Atara Biotherapeutics (B.T.A., E.C.), San Francisco, CA; and Queensland Institute of Medical Research (R.K.), Brisbane, Queensland, Australia.
- Correspondence
Dr. Han mayhan{at}stanford.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Association of innate immune activation with latent Epstein-Barr virus in active MS lesionsJ.S. Tzartos, G. Khan, A. Vossenkamper et al.Neurology, December 07, 2011 -
Article
Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synucleinJohn Woulfe, Madison T. Gray, Munisha S. Ganesh et al.Neurology - Neuroimmunology Neuroinflammation, May 10, 2016 -
Views and Reviews
The evidence for a role of B cells in multiple sclerosisG. Disanto, J.M. Morahan, M.H. Barnett et al.Neurology, March 12, 2012 -
Articles
Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosisS.A. Sargsyan, A.J. Shearer, A.M. Ritchie et al.Neurology, March 10, 2010